We can't find the internet
Attempting to reconnect
14785.1 PFLS-LS
14785.1 PFLS-LS
Zusammenfassung
Characterization and optimization of a novel drug class based on allosteric modulation for applications in neurodegenerative and psychiatric disorders
Weitere Texte
Abstract
The objective of this project is the characterization and optimization of a new class of drug candidates based on allosteric modulation for neurodegenerative and psychiatric diseases. Specifically, allosteric modulators targeting Group III of metabotropic glutamate receptors will be assessed in animal models replicating human Parkinson‟s disease (mGluR4), whereas electrophysiological studies will be carried out on allosteric modulators targeting mGluR4 and mGluR7, in order to investigate their role in modulating synaptic transmission and further characterize their potential therapeutic application in neurodegenerative diseases and anxiolytic disorders. Project results will contribute in the selection of the best candidate compounds for clinical development.
Beteiligte
Graham Dixon
Wirtschaftspartner
graham.dixon@addextherapeutics.com
Addex Pharmaceuticals SA Graham Dixon Chemin des Aulx 12 1228 Plan-les-Ouates GE CH
Ron Stoop
Kontaktperson
Ron.Stoop@unil.ch
CHUV Centre Hospitalier Universitaire Va Centre for Psychiatric Neuroscience Ron Stoop Hôpital de Cery / Route de Cery 1005 Lausanne VD CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2013-05-31
- Enddatum
- 2015-11-30
- Bewilligte Gesamtkosten
- CHF 708030.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%